WO2019059713A3 - 자연살해세포의 제조방법 및 그의 용도 - Google Patents

자연살해세포의 제조방법 및 그의 용도 Download PDF

Info

Publication number
WO2019059713A3
WO2019059713A3 PCT/KR2018/011247 KR2018011247W WO2019059713A3 WO 2019059713 A3 WO2019059713 A3 WO 2019059713A3 KR 2018011247 W KR2018011247 W KR 2018011247W WO 2019059713 A3 WO2019059713 A3 WO 2019059713A3
Authority
WO
WIPO (PCT)
Prior art keywords
natural killer
killer cells
cancer
prevention
killer cell
Prior art date
Application number
PCT/KR2018/011247
Other languages
English (en)
French (fr)
Other versions
WO2019059713A2 (ko
Inventor
조이숙
김한섭
설빛나
최인표
Original Assignee
한국생명공학연구원
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020180113308A external-priority patent/KR102167548B1/ko
Application filed by 한국생명공학연구원 filed Critical 한국생명공학연구원
Priority to US16/649,417 priority Critical patent/US20200407685A1/en
Priority to EP18858679.6A priority patent/EP3686274A4/en
Priority to JP2020516900A priority patent/JP7058728B2/ja
Publication of WO2019059713A2 publication Critical patent/WO2019059713A2/ko
Publication of WO2019059713A3 publication Critical patent/WO2019059713A3/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4613—Natural-killer cells [NK or NK-T]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/50—Colon

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

본 발명은 직접 리프로그래밍을 이용한 자연살해세포 제조방법 및 이로부터 제조된 자연살해세포, 상기 자연살해세포에 특이적인 바이오마커, 상기 자연살해세포를 포함하는 세포치료제, 암 치료 및 예방용 조성물, 상기 자연살해세포를 보관하는 동결보존용 세포바이얼, 상기 직접 리프로그래밍 유도용 배지 키트에 관한 것이다. 상기 제조방법을 이용하여 제조된 자연살해세포는 증식능 및 암세포 살상능이 우수한 바, 대량생산, 암 치료 및 예방용 조성물로서 유용하게 활용될 수 있다.
PCT/KR2018/011247 2017-09-21 2018-09-21 자연살해세포의 제조방법 및 그의 용도 WO2019059713A2 (ko)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US16/649,417 US20200407685A1 (en) 2017-09-21 2018-09-21 Method for producing natural killer cell and use thereof
EP18858679.6A EP3686274A4 (en) 2017-09-21 2018-09-21 METHOD OF MANUFACTURING A NATURAL KILLER CELL AND USE THEREOF
JP2020516900A JP7058728B2 (ja) 2017-09-21 2018-09-21 ナチュラルキラー細胞の製造方法及びその用途

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR10-2017-0121980 2017-09-21
KR20170121980 2017-09-21
KR10-2018-0113308 2018-09-20
KR1020180113308A KR102167548B1 (ko) 2017-09-21 2018-09-20 자연살해세포의 제조방법 및 그의 용도

Publications (2)

Publication Number Publication Date
WO2019059713A2 WO2019059713A2 (ko) 2019-03-28
WO2019059713A3 true WO2019059713A3 (ko) 2019-05-23

Family

ID=65810386

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2018/011247 WO2019059713A2 (ko) 2017-09-21 2018-09-21 자연살해세포의 제조방법 및 그의 용도

Country Status (1)

Country Link
WO (1) WO2019059713A2 (ko)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220160769A1 (en) * 2019-03-28 2022-05-26 Korea Research Institute Of Bioscience And Biotechnology Method for producing immunocytes, and use thereof
CN117050940B (zh) * 2023-10-11 2024-01-26 苏州艾凯利元生物科技有限公司 一种制备自然杀伤细胞的方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140023626A1 (en) * 2012-07-23 2014-01-23 Gamida Cell Ltd. Enhancement of Natural Killer (NK) Cell Proliferation and Activity
KR20150015294A (ko) * 2013-07-31 2015-02-10 한국생명공학연구원 직접 리프로그래밍을 통한 유도 도파민성 전구세포 제조방법
KR20150087727A (ko) * 2014-01-22 2015-07-30 한국생명공학연구원 섬유아세포로부터 조혈줄기세포로의 직접 역분화 유도 방법
KR20160136224A (ko) * 2015-05-19 2016-11-29 고려대학교 산학협력단 Oct4가 도입된 인간체세포로부터 직접적 리프로그래밍을 통한 희소돌기아교 전구세포를 유도하는 방법
KR20170098938A (ko) * 2014-12-31 2017-08-30 안트로제네시스 코포레이션 천연 킬러 세포 및 그의 용도

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140023626A1 (en) * 2012-07-23 2014-01-23 Gamida Cell Ltd. Enhancement of Natural Killer (NK) Cell Proliferation and Activity
KR20150015294A (ko) * 2013-07-31 2015-02-10 한국생명공학연구원 직접 리프로그래밍을 통한 유도 도파민성 전구세포 제조방법
KR20150087727A (ko) * 2014-01-22 2015-07-30 한국생명공학연구원 섬유아세포로부터 조혈줄기세포로의 직접 역분화 유도 방법
KR20170098938A (ko) * 2014-12-31 2017-08-30 안트로제네시스 코포레이션 천연 킬러 세포 및 그의 용도
KR20160136224A (ko) * 2015-05-19 2016-11-29 고려대학교 산학협력단 Oct4가 도입된 인간체세포로부터 직접적 리프로그래밍을 통한 희소돌기아교 전구세포를 유도하는 방법

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CICHOCKI, F.: "GSK3 inhibition drives maturation of NK cells and enhances their antitumor activity", CANCER RESEARCH, vol. 77, 15 October 2017 (2017-10-15), pages 5664 - 5675, XP055611764 *

Also Published As

Publication number Publication date
WO2019059713A2 (ko) 2019-03-28

Similar Documents

Publication Publication Date Title
SA518400424B1 (ar) جزيئات الجسم المضاد لعلاج السرطان
SG10201907164SA (en) Rna containing composition for treatment of tumor diseases
WO2017123675A8 (en) Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells
WO2017044857A3 (en) Methods and compositions for the treatment of glaucoma
MX2018004515A (es) Agentes de anticuerpo especificos para cd19 humano y usos de los mismos.
CA2900779C (en) Compositions and methods for treating neurodegenerative diseases and cardiomyopathy
MX2021002220A (es) Forma cristalina de base libre de lorlatinib.
WO2015048345A3 (en) Compositions and formulations for prevention and reduction of tumorigenesis, cancer cell proliferation and invasion, and methods of production and use thereof in cancer treatment
SG10201808104RA (en) Cenicriviroc for the treatment of fibrosis
WO2016034946A3 (en) Thienopyrroles as histone demethylase inhibitors
MX2015005963A (es) Inhibidores heterociclicos de glutaminasa.
MY192532A (en) Liquid pharmaceutical composition
ZA202001661B (en) Crystalline form of lorlatinib free base hydrate
WO2016200614A3 (en) Bacteria engineered to treat diseases associated with hyperammonemia
WO2016160621A3 (en) Nk-92 cells in combination therapy with cancer drugs
WO2017048809A8 (en) Nk cells exhibiting an adaptive phenotype and methods for preparing and for using
EP4234032A3 (en) Induction medium and methods for stem cell culture and therapy
MX2018013742A (es) Formas cristalinas de crisaborol en forma libre, metodo de preparacion y uso de las mismas.
AU2018337668A1 (en) Improved supraparticles
WO2015200648A8 (en) Use of peptides that block metadherin-snd1 interaction as treatment for cancer
WO2015166089A3 (en) Agent, product and use
WO2019059713A3 (ko) 자연살해세포의 제조방법 및 그의 용도
MX2018000032A (es) Composicion de colorantes basada en antocianina acilada y metodos para usar la misma.
WO2015191449A3 (en) Personal care products containing microalgae or extracts thereof
WO2016093554A3 (ko) 신규한 4-(아릴)-n-(2-알콕시티에노[3,2-b]피라진-3-일)-피페라진-1-카복스아미드 유도체 및 이의 항증식 효과

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18858679

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2020516900

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2018858679

Country of ref document: EP

Effective date: 20200421